Here is the design of a clinical trial:

Official Title: Tuberculosis (TB) Aftermath: a Hybrid Type I Effectiveness-implementation Non-inferiority Randomized Trial in India Comparing Two Active Case Finding (ACF) Strategies Among Individuals Treated for TB and Their Household Contacts

Included conditions:
- Tuberculosis (TB)

Study Armgroups:
- {'label': 'Home-based Active Case Finding (HACF)', 'type': 'ACTIVE_COMPARATOR', 'interventionNames': ['Other: Home-based Active Case Finding (HACF)']}
- {'label': 'Telephonic Active Case Finding (TACF)', 'type': 'ACTIVE_COMPARATOR', 'interventionNames': ['Other: Telephonic Active Case Finding (TACF)']}

Interventions:
- {'type': 'OTHER', 'name': 'Home-based Active Case Finding (HACF)', 'description': 'Existing healthcare workers at the participating NTEP TB units will visit all patient homes at 6 and 12 months post-treatment completion. They will administer a standardized TB symptom screen questionnaire to treated TB cases and their household contacts (HHC). All those who screen positive will have a spot sputum taken at the home for microbiological testing at the TB unit.', 'armGroupLabels': ['Home-based Active Case Finding (HACF)']}
- {'type': 'OTHER', 'name': 'Telephonic Active Case Finding (TACF)', 'description': 'Existing healthcare workers at the participating NTEP TB Units will administer a standardized TB symptom screen questionnaire to the index patient via telephone calls at 6 and 12 months post-treatment completion. The index patient will also be asked about any TB symptoms among household contacts (HHCs). If TB is suspected among any HH members, a home visit will be conducted and spot sputum specimens will be collected for microbiological testing at the TB unit.', 'armGroupLabels': ['Telephonic Active Case Finding (TACF)']}

Primary Outcomes:
- {'measure': 'Rate per 100 person-years of people diagnosed with new or recurrent TB by study arm.', 'description': 'TB disease will be diagnosed as microbiologically confirmed (positive acid fast bacilli smear or positive Xpert® Mycobacterium tuberculosis/resistance to rifampin (MTB/RIF) assays or positive culture) or clinically diagnosed (initiated on TB treatment with no microbiological confirmation).', 'timeFrame': "Within 12 months following index TB patient's treatment completion date."}

Please estimate the sample size based on the assumption: 
The study is powered at 90% to detect non-inferiority with a 10% projected loss to follow-up. For the secondary outcome, there is an assumption of 90% power to see a difference of 60% vs 20% and 80% power to see a difference of 50% vs 25%.
Sample size {14}
        The sample size for index patients (nâ=â1076) includes 538 in the HACF arm and 538 in the TACF arm (1:1 ratio). On average, we will enroll two HHCs per index patient (nâ=â2152). The total estimated sample size for index patients and HHCs is 3228 individuals.
        Data from relevant studies suggest that 10â13% of index patients will develop recurrent TB in each arm [21, 22] and an additional 1â2% of HHCs will develop TB during the study period [58]. Assuming a rate of 12âTB cases per 100 person-years among index patients and 1âTB case per 100 person-years among HHCs, we are powered at 90% to determine that the TACF arm is non-inferior to the HACF arm with a non-inferiority interval of 1.7 per 100 person-years and a sample size of 1076 index patients and two HHCs per index patient (nâ=â2152). This sample size for the primary outcome is adjusted for 10% projected losses to follow-up. For the secondary outcome, we anticipate that 10% (215/2152) of HHCs will be children <â6âyears of age. Data from Pune suggest that approximately 30% of child contacts will have been screened for TB and either initiated on TB therapy or TPT [59]. Thus, we anticipate 70 eligible children in each study arm and hypothesize >â60% to be screened and initiated on TB therapy or TPT in the HACF arm and less than 20% in the TACF arm. We will have at least 90% power to see a difference of 60% vs 20% and 80% power to see a difference of 50% vs 25%.
        For objective 2, we will conduct a total of 40 in-depth interviews with index patients (20 with and 20 without recurrent TB) and one HHC for each patient (40 total). We will also interview 20 HCWs to achieve a total sample size of 100. We will use purposive sampling to obtain a maximum variation sample by study arm, as well as gender and age group for index patients, HHCs, and a range of HCW types and levels.